Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

Now Viewing

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

Video content above is prompted by the following:

IMMagine-1 Phase 2 Study of Anitocabtagene Autoleucel in R/R MM

Background & Objective:
The iMMagine-1 trial evaluates anitocabtagene autoleucel (anti-BCMA chimeric antigen receptor [CAR] T-cell therapy) in patients with R/R MM. Preliminary results focus on efficacy and safety in heavily pretreated patients, including those refractory to triple-class (proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies) and penta-class therapies.

Preliminary Efficacy:

• High response rates were observed, even in penta-refractory patients, suggesting durable disease control in a population with limited treatment options.
• Depth of response correlated with improved progression-free survival, reinforcing the potential of BCMA-targeted CAR T therapy in later-line settings.

Safety Profile:

• Toxicities were consistent with prior CAR T therapies, including cytokine release syndrome and neurotoxicity, but were generally manageable.
• Further follow-up is needed to assess long-term safety and durability of responses.

Clinical Implications:

• Impact on Treatment Strategies:
• The efficacy in triple- and penta-refractory patients may shift treatment paradigms, positioning BCMA-targeted CAR T therapy earlier in the disease course.

• Potential integration into sequencing strategies for R/R MM, especially in those failing standard regimens
• Challenging Existing Paradigms:
• These results reinforce the role of CAR T therapies in overcoming resistance mechanisms in heavily pretreated myeloma.

• The durability of response may challenge the reliance on continuous therapy models, offering the possibility of fixed-duration treatment with sustained benefit.
• Future Directions:
• Optimization of patient selection and bridging strategies

• Comparative studies with bispecific antibodies and other emerging BCMA-directed therapies

These findings highlight anitocabtagene autoleucel as a promising therapeutic option in the evolving R/R MM landscape, warranting continued investigation in larger cohorts.